ST葫芦娃2月24日公告，公司近日收到国家药品监督管理局核准签发的吸入用异丙托溴铵溶液《药品注 册证书》。2ml：0.25mg的吸入用异丙托溴铵溶液可与吸入性β-受体激动剂合用于治疗急性或慢性哮喘 引起的可逆性气道阻塞。2ml：0.5mg的吸入用异丙托溴铵溶液作为支气管扩张剂用于慢性阻塞性肺疾 病，包括慢性支气管炎和肺气肿，引起的支气管痉挛的维持治疗。该药品可与吸入性β受体激动剂合用 于治疗慢性阻塞性肺疾病，包括慢性支气管炎和哮喘，引起的急性支气管痉挛。公司对该产品已累计投 入研发费用590.89万元（未经审计）。 ...

海南葫芦娃药业集团股份有限公司 关于获得吸入用异丙托溴铵溶液药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）近日收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的关于吸入用异丙托溴铵溶液《药品 注册证书》。现将有关情况公告如下： 一、药品基本情况 药物名称：吸入用异丙托溴铵溶液 剂型：吸入制剂 注册分类：化学药品 4 类 规格：2ml：0.25mg（按 C₂₀H₃₀BrNO₃计）、2ml：0.5mg（按 C₂₀H₃₀BrNO₃计） 证券代码：605199 证券简称：ST 葫芦娃 公告编号：2026-011 根据国家药监局网站数据查询，截至本公告披露日，除本公司外，国内已经批 准上市的吸入用异丙托溴铵溶液生产企业有 29 家。 截至目前，公司对该产品已累计投入研发费用人民币 590.89 万元（未经审计）。 上市许可持有人：海南葫芦娃药业集团股份有限公司 受理号：CYHS2403031、CYHS2403032 药品批准文号：国药准字 H2026336 ...

Group 1 - The core viewpoint of the news is that several gold mining companies, including Lingbao Gold and Laopu Gold, experienced significant stock price increases following the announcement of the latest quarterly review results by the Hang Seng Index Company [1] - Lingbao Gold and Laopu Gold saw their stock prices rise over 6%, while Shandong Gold increased by 4% and Zijin Mining by 3% [1] - The inclusion of Ningde Times, Luoyang Molybdenum, and Laopu Gold in the Hang Seng Index, along with Lingbao Gold's addition to the Hang Seng Composite Index, contributed to the positive market reaction [1]

经济观察网 ST葫芦娃（605199）（605199.SH）近期面临业绩预亏、新产品获批、监管调查及控股股东 股份冻结等多重情况。 业绩经营情况 公司预计2025年全年归属于上市公司股东的净利润将出现亏损，区间为-21,000万元至-31,000万元。业 绩变动主要受行业政策调整、市场环境变化、新生产基地转固导致折旧增加以及财务费用上升等因素影 响。 产品研发进展 股东质押股份 控股股东海南葫芦娃投资发展有限公司所持有的部分公司股份被司法冻结，占总股本的5.97%，这可能 对公司控制权稳定性带来不确定性。 公司全资子公司获得国家药监局核准签发的"复方聚乙二醇电解质口服溶液"药品注册证书，该药品用于 治疗慢性便秘和粪便嵌塞。此前，公司还获得了"依巴斯汀口服溶液"的药品注册证书。这些新产品的获 批有助于丰富公司产品线，但其未来销售业绩受政策和市场因素影响存在不确定性。 监管情况 公司及董事长刘景萍因涉嫌信息披露违法违规，于2025年12月28日被中国证监会立案调查，目前调查仍 在进行中。由于此前信息披露问题，公司面临投资者诉讼索赔的风险。因2024年财务报告内部控制被出 具否定意见审计报告，公司股票自2025年4 ...

Group 1 - The core point of the article is that ST Huluwawa's wholly-owned subsidiary, Guangxi Weiwei Pharmaceutical Co., Ltd., has received the drug registration certificate for the compound polyethylene glycol (3350) electrolyte oral solution from the National Medical Products Administration [1] Group 2 - The drug is named compound polyethylene glycol (3350) electrolyte oral solution [1]

Core Viewpoint - ST Huluwawa (605199.SH) announced that its wholly-owned subsidiary, Guangxi Weiwei Pharmaceutical Co., Ltd., has received the drug registration certificate from the National Medical Products Administration for the compound polyethylene glycol (3350) electrolyte oral solution, which is indicated for the treatment of chronic constipation and fecal impaction [1] Company Summary - ST Huluwawa's subsidiary Guangxi Weiwei has successfully obtained regulatory approval for a new product, enhancing its portfolio in the gastrointestinal treatment market [1] - The approved product, compound polyethylene glycol (3350) electrolyte oral solution, targets a significant health issue, chronic constipation, which may lead to increased market demand [1]

Core Viewpoint - The company ST HuLuWa has received approval from the National Medical Products Administration for its subsidiary Guangxi Weiwei Pharmaceutical Co., Ltd. to market a new oral solution for chronic constipation and fecal impaction, enhancing its product line [1] Group 1 - The approved drug is a compound polyethylene glycol (3350) electrolyte oral solution, developed by Norgine, and contains active ingredients such as polyethylene glycol 3350, sodium chloride, potassium chloride, and sodium bicarbonate [1] - The company has invested a total of RMB 762,100 in research and development for this drug [1] - The approval of the drug registration certificate will further enrich the company's product offerings [1]

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2026-010 海南葫芦娃药业集团股份有限公司 关于全资子公司获得复方聚乙二醇（3350） 电解质口服溶液药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司全资子公司广西维威制药有限公司（以下简 称"广西维威"）近日收到国家药品监督管理局（以下简称"国家药监局"）核准签 发的关于复方聚乙二醇（3350）电解质口服溶液的《药品注册证书》。现将有关情况 公告如下： 一、药品基本情况 药物名称：复方聚乙二醇（3350）电解质口服溶液 剂型：口服溶液剂 注册分类：化学药品 3 类 规格：25ml/袋 上市许可持有人：广西维威制药有限公司 药品批准文号：国药准字 H20263335 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符 合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品研发及相关 复方聚乙二醇（3350）电解质口服溶液适用于治疗慢性便秘、粪便嵌塞。 复方聚乙二醇（3350）电解质口服溶液， ...

Group 1 - Intercontinental Oil and Gas focuses on oil exploration and development, with significant operations in Kazakhstan and the Malacca Strait, benefiting from the Hainan Free Trade Port's zero-tariff policy which will reduce equipment import costs and enhance cross-border energy trade efficiency, with a projected 30% increase in trade scale over the next three years [1][34] - Jinpan Technology, a leading manufacturer of high-end power distribution equipment, will benefit from reduced raw material costs and a 15% corporate income tax reduction, enhancing profitability and enabling expansion into the ASEAN power equipment market [2][35] - Hainan Airlines, a major player in the aviation sector, expects a significant increase in passenger traffic due to the visa-free policy for 86 countries and duty-free upgrades, with projected passenger volume exceeding 80 million by 2026 [3][36] Group 2 - Junda Co., a top photovoltaic cell manufacturer, anticipates growth in its solar business due to reduced equipment costs and tax incentives, with plans to participate in Hainan's integrated wind and solar storage projects [4][37] - Caesar Travel, a comprehensive tourism service provider, expects a doubling of cross-border tourism business and a significant increase in tourist arrivals, with projections of 180 million visitors by 2026 [5][38] - Xinda A, a diversified company focusing on motorcycle manufacturing and coal mining, aims to leverage the zero-tariff policy to enhance profitability and expand into the electric vehicle market [6][39] Group 3 - ST Huluwawa, a leading pediatric pharmaceutical company, will benefit from reduced raw material costs and tax incentives, with plans to expand into the ASEAN pharmaceutical market [8][40] - Hainan Ruize, a construction industry leader, anticipates a surge in infrastructure demand with projected investments exceeding 100 billion by 2026, benefiting from the Hainan Free Trade Port's policies [9][42] - Hainan Airport, a key player in airport operations, expects a doubling of cargo business and significant passenger growth due to the visa-free policy and duty-free upgrades [10][43] Group 4 - Hainan Development, an investment platform, anticipates a substantial increase in duty-free sales, projected to exceed 100 billion by 2026, benefiting from the Hainan Free Trade Port's policies [11][45] - Hainan Highway, a major highway operator, expects a significant increase in traffic volume, projected to exceed 200 million vehicles by 2026, benefiting from the integration of tourism and real estate [20][56] - Hainan Rubber, the world's largest natural rubber producer, aims to expand its market presence in ASEAN due to favorable trade policies and tax incentives [21][57]

Core Points - Beijing Rural Commercial Bank announced the public disclosure of its physical precious metals consignment business cooperation institutions for the year 2026 [1] Group 1: Announcement Details - The announcement aims to ensure transparency and inform stakeholders about the institutions involved in the physical precious metals business [1] - A list of cooperation institutions for 2026 includes various companies such as China Gold Coin Corporation and its subsidiaries, Beijing Caishikou Department Store Co., Ltd., and others [2] - The listed institutions have established formal cooperation with Beijing Rural Commercial Bank to conduct physical precious metals consignment business in 2026 [2] Group 2: Contact Information - Stakeholders can contact Beijing Rural Commercial Bank at hotline 96198 for any inquiries or further information regarding the cooperation institutions [2]